Answers are grounded in this paper and cite their sources.
This is a critical narrative review focusing on HR+/human epidermal growth factor receptor 2-negative (HER2–) de novo metastatic breast cancer in terms of genomic, biological, pathological, and clinical features and outcomes after systemic and locoregional treatments, outlining differences with recurrent metastatic breast cancer.
No takes yet. Share an insight, caveat, or question.
Torrisi et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: